BioCentury | Feb 11, 2019
Distillery Therapeutics

Cancer

...INDICATION: Mesothelioma Cell and mouse studies suggest GHRH receptor antagonists could help treat malignant pleural mesothelioma...
...mesothelioma (MPM). In two human-derived MPM cell lines and patient-derived MPM cells, two previously identified GHRH...
...hypothalamic peptide GHRH receptor antagonist, in preclinical testing for breast, ovarian and prostate cancer. TARGET/MARKER/PATHWAY: Growth hormone-releasing hormone (GHRH) receptor...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

...INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart...
...rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte models of phenylephrine-induced hypertrophy, GHRH...
...Pharmaceuticals AG, BL&H Co. Ltd. and Sanofi market Egrifta tesamorelin, a GHRH analog that agonizes GHRH...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Cancer

...suggest antagonizing the GHRH receptor could help treat retinoblastoma. In a human retinoblastoma cell line, GHRH...
...in normal eye-derived cell lines. In the retinoblastoma cell line and primary retinoblastoma cells, two GHRH...
...the GHRH receptor antagonist BIS-1602 in preclinical testing for breast, ovarian and prostate cancers. TARGET/MARKER/PATHWAY: Growth hormone-releasing hormone (GHRH) receptor...
BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

...Endocrine/metabolic disease INDICATION: Dyslipidemia Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with...
...GHRH receptor levels in the small intestine than normal rats. In the rat model, a GHRH...
...peptide GHRH receptor antagonist, in preclinical testing to treat breast, ovarian and prostate cancers. TARGET/MARKER/PATHWAY: Growth hormone-releasing hormone (GHRH) receptor...
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

...Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest GHRH receptor agonists could improve engraftment...
...of islet cell transplant to treat diabetes. In a rat pancreatic β cell line, the GHRH...
...Pharmaceuticals has MR-409 in preclinical testing for myocardial infarction (MI). Aileron Therapeutics Inc. has the GHRH...
BioCentury | Nov 2, 2015
Company News

Biscayne Pharmaceuticals, Insero Health deal

...Biscayne merged with Insero on June 30. Biscayne is developing growth hormone-releasing hormone (GHRH) receptor analogs. Biscayne’s lead compound is...
BioCentury | Sep 8, 2014
Emerging Company Profile

Biscayne: Antagonizing cancer

...in bone metastases in prostate cancer patients. According to Reich, tumor cells produce the growth hormone-releasing hormone (GHRH...
...other companies that have publicly disclosed peptide antagonist programs targeting GHRH. Biscayne also has a GHRH...
...al. " Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH...
BioCentury | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

...a growth hormone secretagogue Phase II Akela Pharma Inc. GHRH analog Peptide analog of growth hormone-releasing hormone (GHRH...
BioCentury | Jun 9, 2014
Company News

Inovio, Plumbline Life Sciences Inc. deal

...being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone ( GHRH...
...license to Inovio electroporation delivery systems. Inovio, which retains rights to human applications of the GHRH...
BioCentury | Nov 19, 2013
Financial News

Aileron raises $30 million series E

...hydrocarbon linker. The company's lead compound, ALRN-5281 , is a long-acting growth-hormone releasing hormone ( GHRH...
Items per page:
1 - 10 of 81